CME Sessions at EANM’05

EANM’05 – CME Session II

Oncology PET/CT
October 16, 2005, 11:30 – 13:00
Current role of PET and PET/CT in managing lymphoma patients

Moderator: E. Bombardieri (Milan)
CoModerator: J.N. Talbot (Paris)

E. Morra (Milano):
Malignant lymphomas: prognostic factors and treatment
J.N. Talbot (Paris):
PET/CT in staging and restaging
O. Schober (Muenster):
PET/CT in assessing therapy response

Educational objectives:

Upon completion of this course the attendee will be able to:

  1. understand the criteria of classification of lymphomas; pathology and prognostic factors
  2. understand the principles of management and treatment results
  3. be aware of the clinical role of PET in the diagnosis and staging lymphoma’s patients
  4. discuss the experience with FDG-PET and FDG-PET/CT in evaluating tumour response to chemotherapy and radiotherapy (early and late response assessment)
  5. understand the role of PET as a tool to optimize radiotherapy on the basis of FDG uptake
  6. know the clinical role of PET in the clinical management of paediatric lymhomas


This course has been designed for physicians with a background in nuclear medicine and oncology involved or interested in the diagnosis of lymphomas. The first lecture will provide a general overview about the classification and the prognosis of non-Hodgkin’s lymphoma and Hodgkin’s disease, that has improved significantly as a result of the increased knowledge of pathology patterns and new therapeutic strategy but also because of the advances in imaging techniques. The second lecture will discuss the role of FDG-PET/CT as a very effective method for staging and re-staging patients. In fact the morphologic imaging (CT, MRI, echography) provide in most instances accurate definition on nodal involvement, but they are not able to depict lymphoma in normal-sized lymph nodes or differentiate nodal involvement from nodal enlargement due to other causes. After treatment the diagnosis of residual masses is an important clinical issue, since the following therapeutic strategies are indicated only if viable tumor is still present. The final lecture will present the role of PET after completion of therapy to assess response and also during therapy to predict response. Persistent tumoral FDG stages after a few cycles of chemotherapy can be predictive of treatment failure. PET/CT will be discussed also as an useful tool in order to plan radiotherapy. PET/CT has the advantage of defining biologically active or tumour-bearing areas that would not be detected by conventional radiology. Furthermore, target volumes may be modified by the use of PET, which may have a significant impact in the modern era of three-dimensional radiotherapy. Other issues that will be considered in this course are the potential use of PET in routine post-treatment follow-up of asymptomatic patients and the impact of PET on the management of paediatric patients with malignant lymphoma.

Key Words:

  1. Prognosis and treatment of non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD)
  2. PET and PET/CT in staging NHL and HD
  3. PET in prediction/assessment of tumour response
  4. PET and PET/CT in radiation treatment planning
  5. PET in paediatric patients
Back to top